




## SOMNOMED EXCEEDS 200,000 PATIENTS

10<sup>th</sup> November 2014, SomnoMed Limited (ASX: SOM) announced today that it had exceeded the benchmark of 200,000 non-invasive medical devices fitted to patients to treat obstructive sleep apnoea since start of its operations in 2004.



Dr. Peter Neustadt, Executive Chairman of SomnoMed said, “We are proud to have reached this milestone. It took us eight years to reach the first 100,000 patients and only two and a half years to reach the next 100,000. The last 50,000 devices were fitted in only 12 months.”

“Whilst 200,000 SomnoDent® devices fitted to patients is an important milestone, we believe it is only the beginning of our long-term growth,” he said. “We expect this sales trend to continue with sales growth driven by a growing acceptance among medical specialists, increased levels of reimbursement by insurers and expansion into new markets.”

SomnoMed is the leading global company in COAT™ (Continuous Open Airway Therapy), which uses an oral appliance to treat obstructive sleep apnea. COAT™ is becoming an increasingly popular alternative to CPAP. CPAP which uses a stream of compressed air that is blown through a face mask to keep the airways open during the night is medically effective but rejected as too cumbersome and invasive by a great number of patients. Patient compliance is a principal problem for CPAP makers and has not been resolved despite significant improvements of pumps, pressure control and the quality of masks.

SomnoMed makes its SomnoDent® appliances under strict medical production regulations, has proven its efficacy in 18 medical studies and has received regulatory approvals such as FDA, CE, TGA and others. It now operates in 26 countries in the three principal regions of Asia-Pacific, Europe and North America.

Recent research indicates that SomnoDent® appliances can treat up to 80% of patients medically successfully, with most of the remaining 20% achieving measurable improvements.

“There are very few patients which will not see improvements in their conditions. This does not only manifest itself in a high compliance rate but also in an astonishing percentage of our patients volunteering to tell us how satisfied and happy they are with the results of the SomnoDent®,” said Dr. Neustadt.

**Contact:** Dr. Peter Neustadt – Executive Chairman and CEO, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592 - mobile

### About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 200,000 patients in 26 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>